

Special Issue

Antibacterial Applications of Bioactive Nanoparticles

Message from the Guest Editors

Nanoparticles are small particles, and have attracted significant interest from scientists due to their multiple applications in diverse fields of science. The application of these bioactive nanoparticles in the biomedical field offers many revolutionary solutions regarding the development of multi-functionalized drugs and products with antibacterial properties. Antibiotic-resistant microorganisms cause life-threatening diseases in humans. The development of novel antibacterial agents is a key solution to this issue. Therefore, bioactive nanoparticles could be promising agents to control these multidrug-resistant bacteria. Various green methods could be used for the facile, rapid and mass production of nanoparticles. The synthesized nanoparticles could be utilized as antibacterial agents to control various pathogenic bacteria. This research topic will focus on the antibacterial applications of bioactive nanoparticles and is an open forum in which scientists/researchers may share their knowledge, investigations and findings in this promising field.

Guest Editors

Dr. Md Amdadul Huq

Department of Life Sciences, College of BioNano Technology, Gachon University, Seongnam 13120, Gyeonggi-do, Republic of Korea

Dr. Shahina Akter

Department of Food Science and Biotechnology, Gachon University, Seongnam 461-701, Republic of Korea

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/163540

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).